The planned filing comes amid heightened scrutiny of the FDA’s rare disease stance and a year after Prime deprioritized the ...
The firm believes that clinical data generated to date from two patients may be sufficient to support accelerated approval of PM359.
Discover how prime editing is redefining the future of medicine by offering highly precise, safe, and versatile DNA corrections, bringing hope for more effective treatments for genetic diseases while ...
A new genome editing tool—minimal versatile genetic perturbation technology (mvGPT)—can achieve simultaneous and orthogonal gene editing and gene regulation in human cells. The coming together of ...
CAMBRIDGE, Mass., Dec. 07, 2025 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, ...
Researchers at the Francis Crick Institute have demonstrated that a genetic method called "pooled prime editing" can screen hundreds of variants in a gene at once and identify which variants affect ...
On track to file IND and/or CTA for Wilson Disease and AATD programs in 1H 2026 and mid-2026, respectively; initial clinical data for both ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results